3 enrolling by invitation. 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Enrolling by invitation 3 |
Follow Digestive System Neoplasms: new trials by email Literature Review of Digestive System Neoplasms trials Research Report on Digestive System Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study Cabozantinib, Zanzalintinib, Atezolizumab - Cancer, Renal Cell Carcinoma (RCC) | Phase 3 | Enrolling by invitation | Exelixis | 5000 | 2026-07-30 | 2026-10-28 |
| Immunochemotherapy ± Salvage Chemoradiation for Local Recurrence of Esophageal Squamous Cell Carcinoma After Definitive Chemoradiotherapy Sintilimab Combined With Docetaxel Monotherapy - Esophageal Squamous Cell Carcinoma (ESCC) | Phase 3 | Enrolling by invitation | Ye jinjun | 79 | 2024-08-01 | 2025-06-12 |
| Primary Percutaneous Stenting Above the Ampulla Versus Endoscopic Drainage for Unresectable Malignant Hilar Biliary Obstruction Primary percutaneous stenting (PPS), Endoscopic biliary drainage - Cholangiocarcinoma Non-resectable, Gall Bladder Cancer | Phase 3 | Enrolling by invitation | Erasmus Medical Center | 148 | 2023-08-09 | 2024-11-04 |
Carcinoma, Hepatocellular (1) · Carcinoma, Renal Cell (1) · Colorectal Neoplasms (1) · Esophageal Squamous Cell Carcinoma (1) · Gallbladder Neoplasms (1) · Neoplasms (1) · Prostatic Neoplasms (1)
Digestive System Diseases (3) · Neoplasms by Site (3) · Carcinoma (2) · Gastrointestinal Diseases (2) · Gastrointestinal Neoplasms (2) · Neoplasms (2) · Neoplasms by Histologic Type (2) · Neoplasms, Glandular and Epithelial (2) · Adenocarcinoma (1) · Biliary Tract Diseases (1) · Biliary Tract Neoplasms (1) · Carcinoma, Squamous Cell (1) · Colonic Diseases (1) · Esophageal Diseases (1)
Carboplatin (1) · Dexamethasone (1) · Gastroscopy (1) · High-Energy Shock Waves (1) · Loperamide (1) · Nivolumab (1) · Omeprazole (1) · Prednisone (1) · abiraterone (1) · atezolizumab (1) · atropine sulfate-diphenoxylate hydrochloride drug combination (1) · cabozantinib (1) · enzalutamide (1)
Erasmus Medical Center (1) · Exelixis (1) · Ye jinjun (1)
China (1) · Netherlands (1) · United States (1)